Efficacy of remdesivir for hospitalized COVID-19 patients with end stage renal disease

Table 2 Main effect parameter estimates for the primary outcomes and covariates

	Outcome: Max O2			Outcome: Ventilation			Outcome: Time to Mortality
Variable	PE	X2 (1)	p	PE	X2 (1)	P value	PE	X2 (1)	P value
Age	0.32	3.25	0.0712	0.04	0.56	0.4562	0.05	1.75	0.1860
Tobacco use	8.59	3.82	0.0507	1.29	0.91	0.3399	-0.89	0.91	0.3398
Female Sex	-9.49	5.43	0.0198	-2.94	3.80	0.0511	0.05	< 0.01	0.9529
Black, Hispanic, and Other races	7.02	2.69	0.1011	2.14	1.96	0.1614	1.18	1.91	0.1672
Obesity	5.35	1.36	0.2444	1.46	0.74	0.3904	0.32	0.16	0.6932
Diabetes	-20.59	5.21	0.0224	-4.06	3.61	0.0575	-4.17	9.25	0.0024
High d dimers	-21.50	2.22	0.1358	-0.01	< 0.01	0.9971	-5.86	7.41	0.0065
Remdesivir	-25.93	6.65	0.0099	-28.52	22.98	< 0.0001	-5.03	7.42	0.0065

PE stands for parameter estimate. For Max O2, this is the average difference between the specified group and the overall mean. For ventilation, this represents the log odds difference between the specified group and the overall odds of being on a ventilator. For time to mortality, this represents the difference in risk of mortality as a function of time for the specified group relative to the overall risk of mortality for corona virus disease 2019 patients. Because age was specified as a continuous value, the values in PE represent the change in mean, odds, or risk for a one-year increase or decrease in age.